Trial · NCT07896668
Pucotenlimab and Anlotinib in Combination With Chemotherapy
NCT07896668, Phase 2, Recruiting, Zhejiang Cancer Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pucotenlimab and Anlotinib in Combination With Chemotherapy. Trials, record NCT07896668. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07896668
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pucotenlimab and Anlotinib in Combination With Chemotherapy
- NCT number
- NCT07896668
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 34 participants, estimated
- Lead sponsor
- Zhejiang Cancer Hospital
- Conditions
- Breast Cancer
- Interventions
- LP
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Total pathological complete response (tpCR) rate | Within 30 days of definitive surgery | ypT0/Tis ypN0 |
| Secondary | Objective response rate (ORR) | Prior to surgery | |
| Secondary | Breast pathological complete response (bpCR) rate | Within 30 days of definitive surgery | |
| Secondary | tpCR rate in patients with PD-L1 expression | Within 30 days of definitive surgery | |
| Secondary | Event free survival (EFS) | From date of first dose until the first documented event or up to 5 years | EFS is defined as the time from the date of first dose to the first occurrence of any of the following events: disease progression precluding curative-intent surgery, local or distant recurrence, or death from any cause. For participants without any events, EFS will be censored at the date of the last known event-free assessment. |
| Secondary | Disease free survival (DFS) | From date of surgery up to 5 years | DFS is defined as the time from the date of surgery to the first occurrence of loco-regional or distant recurrence, or death from any cause. For participants without an event, DFS will be censored at the date of the last known disease-free assessment. |
| Secondary | Incidence of Adverse Events (AEs) | Up to 30 days post-last dose (with 7-day window) or until new therapy/adjuvant therapy, whichever first. | |
| Secondary | Health-Related Quality of Life Assessed by EORTC QLQ-C30 | at baseline and within 3 weeks after completion of the last neoadjuvant therapy cycle. | |
| Secondary | Health-Related Quality of Life Assessed by EORTC QLQ-BR45 | at baseline and within 3 weeks after completion of the last neoadjuvant therapy cycle. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07896668
GET https://conductscience.org/api/trials/v1/NCT07896668/registered